Barbara Ann Araneo
Hearing Aid Provider in Salt Lake City, UT

5635496, Jun 3, 1997

Jun 7, 1995

8/480745

Raymond A. Daynes - Park City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61K 3156

514169

The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA, DHEA derivatives or DHEA congeners to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA, DHEA derivatives or DHEA congeners to a patient.

5587369, Dec 24, 1996

Jun 7, 1995

8/480744

Raymond A. Daynes - Park City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61K 3156

514178

The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA, DHEA derivatives or DHEA congeners to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA, DHEA derivatives or DHEA congeners to a patient.

5795872, Aug 18, 1998

Sep 19, 1995

8/530529

Joseph W. Ricigliano - Salt Lake City UT
Barbara A. Araneo - Salt Lake City UT

Pharmadigm, Inc. - Salt Lake City UT

A61K 4500, A61K 4505, C12N 1511, C12N 1563

514 44

The present invention is directed to a DNA construct which is useful for immunization or gene therapy. The construct of the invention comprises muscle specific regulatory elements, such as a promoter or a promoter and one or more enhancer elements, and a DNA sequence under control of the muscle specific regulatory elements. Several DNA sequences may be incorporated into the DNA construct. In one embodiment, the DNA sequence codes for an antigen, antigenic determinant or an epitope of an antigen. In a second embodiment, the DNA sequence is a normal muscle gene which is effected in a muscle disease. In a third embodiment, the DNA sequence is an antisense for blocking an abnormal muscle gene. In a fourth embodiment, the DNA sequence codes for a protein which circulates in the mammalian blood or lymphatic systems. The present invention is useful for ameliorating the effects of diseases of muscle by expression of the normal gene or blocking abnormal gene expression within muscle cells, for the heterologous expression of a transgene which codes for a circulating protein or a protein which modifies a disease state in which muscle is not primarily involved and for vaccine development.

5583126, Dec 10, 1996

May 19, 1995

8/446568

Raymond A. Daynes - Park City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A01N 4500

514170

The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA or DHEA derivatives to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA or DHEA derivatives to a patient. Suitable derivatives of DHEA include, among others, 16. alpha. -bromo-DHEA, androstenediol and derivatives which have side chains at the 4' and/or 7' positions, which do not destroy the native activity of DHEA but which are capable of inhibiting sulfotransferase to prevent the conversion of DHEA to DHEA-S.

5540919, Jul 30, 1996

Feb 16, 1993

8/018471

Raymond A. Daynes - Salt Lake City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61K 3156, A61K 3159, A61K 3820, A61K 3939

424 852

Disclosed is a method for enhancing the production of T cell lymphokines, which comprises exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to an appropriate concentration of at least one particular steroid hormone prior to cellular activation. Also disclosed are applications of the method for clinically diagnosing abnormal interleukin production, maintaining in vitro tissue cultures of T cells, overcoming certain types of immunosuppression caused by elevated GCS levels, caused by endogenous production or exogenous administration, use as a vaccine adjuvant to selectively direct the vaccine-induced immune response down a protective, rather than a potentially pathologic or non-protective, immunologic pathway, as a treatment for naturally occuring aging-related decreases in immune function, as a treatment for stress or trauma-induced decreases in immune function, and as an agent to facilitate desensitization to agents to which a warm-blooded animal is allergic.

5753640, May 19, 1998

Dec 29, 1995

8/580716

Barbara A. Araneo - Salt Lake City UT
Urszula Orlinska - Hockessin DE
Imad S. Farrukh - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT
Pharmadigm, Inc. - Salt Lake City UT

A61K 3156

514178

The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering dehydroepiandrosterone-3-sulfate (DHEAS), DHEA or a DHEA congener.

5977095, Nov 2, 1999

Jun 5, 1997

8/870234

Barbara A. Araneo - Salt Lake City UT
Raymond A. Daynes - Park City UT
Urszula Orlinska - Hockessin DE
Imad S. Farrukh - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT
Pharmadigm, Inc. - Salt Lake City UT

A61K 3156

514178

The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (bums), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing, or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering a dehydroepiandrosterone (DHEA) derivative as defined herein.

5824313, Oct 20, 1998

Jun 7, 1995

8/480567

Raymond A. Daynes - Park City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61K 3900, A61K 39145, A61K 39155, A61K 3907

4241841

The invention relates to a vaccine which comprises an antigen and a lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include, but are not limited to, 1,25-dihydroxy Vitamin D. sub. 3, biologically active Vitamin D. sub. 3 derivatives which are capable of activating the intracellular Vitamin D. sub. 3 receptor, all trans-retinoic acid, retinoic acid derivatives, retinol, retinol derivatives and glucocorticoid. The vaccine composition may further comprise an immune response augmenting agent. The immune response augmenting agent enhances T cell lymphokine production. Suitable immune response augmenting agents include, but are not limited to, dehydroepiandrosterone (DHEA), DHEA congeners and DHEA-derivatives. The invention also relates to a method for inducing an antigen-specific mucosal immune response in a subject vertebrate animal which comprises administering a vaccine which comprises an antigen and a lymphoid organ modifying agent to a site which drains into a peripheral lymph compartment. Alternatively, the method comprises separately administering the lymphoid organ modifying agent and a vaccine containing an antigen to the same site.

5753237, May 19, 1998

Sep 21, 1994

8/309704

Raymond A. Daynes - Park City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61K 3156, A61K 3159, A61K 3900

4242781

Methods for augmenting immune responses in immunodeficient individuals are disclosed. The methods utilize steroid hormones, particularly DHEA, its prohormones (particularly DHEA-S), and DHEA-cogeners. Additional embodiments of the invention include pharmaceutical compositions for use in the methods.

5859000, Jan 12, 1999

Nov 7, 1997

8/966385

Tad Dowell - Salt Lake City UT
Steven D. Norton - Salt Lake City UT
Barbara A. Araneo - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT
Pharmadigm, Inc. - Salt Lake City UT

A61K 3156

514178

The present invention is directed to a method for reducing mast cell mediated allergic reactions, including mast cell mediated allergy and asthma. Mast cell mediated allergic reactions, including type I hypersensitivity reasponse to allergens and asthma, are reduced by administering a dehydroepiandrosterone (DHEA) derivative to a patient in a manner which quickly raises blood levels of the active agent.